Theramex Reinforces its Commitment to Women on International Women’s Day
International Women’s Day is an important date on the calendar to recognise and celebrate the social, economic, culture, political, scientific and many more achievements of women globally. At Theramex, every day is considered International Women’s Day because our sole focus is on the health needs of women. Although we celebrate the day, this is no time to stop or pause as there are many challenges to overcome for a fairer and equitable world. We celebrate this day by coming to work to add value to our patients propelled by our passion to improve women’s health and improve her quality of life.
“IWD reminds us that our work is crucial in the care and improvement of women’s health, as they navigate through different stages of life. Over the year we have collaborated with some amazing organisations to raise money for women in need, increase awareness on issues such as domestic violence and support organisations focused on education like Binti International, a charity who raise awareness and educate around period poverty. Our volunteer efforts compliment the work we are doing inside Theramex to make a difference in the lives of women and we are just getting started” said Robert Stewart, Theramex CEO.
This IWD, we will work even harder, dedicating our time to supporting and uplifting women. We provided the opportunity for our entire team to carve out time from their busy schedule to participate in fundraising activities and/or volunteering at a partnered charity.
“IWD 2022 theme, #BreakTheBias, is especially relevant to us, because we ardently believe that breaking the bias can only be achieved with true commitment from each and every one of us. We are committed to breaking the bias around the menopause in the workplace, we are committed to break the bias surrounding the psychological impact of domestic abuse through our CSR work” said Anjuna Kalsi, Theramex, Chief Human Resources Officer.
“As a new addition to the team, I am so excited to be part of Theramex. Being here every day to make a difference for a more inclusive and healthy world for women is a true inspiration” said Camilla Harder Hartvig, Theramex Chief Commercial Officer.
With this being Theramex’s 5th International Women’s Day we have partnered with some amazing organisations including Where Women Work to showcase the women within Theramex and the achievements they have gained throughout their careers. Our choice charity for our global Headquarters is Woman’s Trust, a mental health charity who provide free counselling and therapy for women who have experienced domestic abuse; we will be supporting other domestic abuse charities across the globe in communities where we work.
We look forward to the celebration but also for the opportunity to make a difference.
About Theramex
Theramex is a leading global speciality pharmaceutical company dedicated to women and their health. We support women at every stage of their lives by providing a broad portfolio of innovative and established brands covering contraception, fertility, menopause and osteoporosis. Our commitment is to listen to and understand our patients, serve their needs and offer healthcare solutions to help improve their lives. Our vision is to be a lifetime partner for women and the healthcare professionals who treat them by providing patient-focused and effective solutions that care for and support women through every stage of life.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220208005669/en/
Contact information
Jesús López | Associate Director, Communication & Digital | Jesus.Lopez@Theramex.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
New Multi-Mission Beechcraft King Air Demonstrator Unveiled at Paris Air Show16.6.2025 09:30:00 EEST | Press release
Textron Aviation Inc., a Textron Inc. (NYSE: TXT) company, announced its new multi-mission Beechcraft King Air demonstration aircraft will be making its show and European debut at the 2025 Paris Air Show. The aircraft is equipped to showcase a wide range of missions available on the versatile and reliable Beechcraft King Air platform, and will be on static display Monday, June 16, through Thursday, June 19, at the Textron Pavilion A2. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250615940392/en/ From Wichita, Kansas to Paris, France: Beechcraft King Air demonstrator makes international debut “The King Air’s acquisition and operation cost, combined with excellent speed, range and payload capacity make it an excellent value for a wide range of special missions,” said Bob Gibbs, vice president, Special Missions Sales. “The best-selling turboprop serves as an ideal platform for intelligence, surveillance and reconnaissance, ut
Ant International Announces Sustainability Framework, Serving 100 mn Merchants to Advance Inclusive Growth in Re-globalisation16.6.2025 08:00:00 EEST | Press release
Ant International, a leading global digital payment, digitisation and financial technology provider, today announced its Sustainability Framework in its first independent Sustainability Report. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250615891282/en/ Ant International announces Sustainability Framework in its Inaugural Sustainability Report A New Chapter of Growth with New Mission and Vision at a Critical Moment 2024 is a transformative year for Ant International, which became independent after a reorganisation of Ant Group. With headquarters in Singapore and over 30 offices around the world, Ant International provides cross-border digital payment, commerce and finance solutions to merchants and financial institutions, connecting 100 million+ merchants to global consumers across its 4 business units: global e-wallet gateway service (Alipay+), merchant payment service (Antom), cross-border business account service (Wor
Cosmetics Industry Icon Leonard A. Lauder, Chairman Emeritus, The Estée Lauder Companies, Passes Away15.6.2025 19:54:00 EEST | Press release
It is with deep sadness that The Estée Lauder Companies Inc. (NYSE: EL) announces that Chairman Emeritus Leonard A. Lauder passed away on June 14, at the age of 92, surrounded by family. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250615313230/en/ Leonard A. Lauder Mr. Lauder was born in 1933 in New York City, the oldest son of Estée and Joseph H. Lauder, the founders of The Estée Lauder Companies. He was a graduate of the Bronx High School of Science, the University of Pennsylvania’s Wharton School, and the Officer Candidate School of the United States Navy. Mr. Lauder studied at Columbia University’s Graduate School of Business. He served as a lieutenant in the U.S. Navy and as a Navy reservist, for which the U.S. Navy Supply Corps Foundation later recognized him with its Distinguished Alumni Award. He formally joined Estée Lauder in 1958, and for more than six decades, Mr. Lauder was a visionary and an innovator, helpi
Positive Late-Breaking Data for Incyte’s First-in-Class mutCALR-targeted therapy INCA033989 in Essential Thrombocythemia Presented at EHA202515.6.2025 10:15:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced the first clinical data from two studies evaluating the safety, tolerability and efficacy of INCA033989, a novel, first in class, Incyte-discovered, targeted monoclonal antibody in patients with mutant calreticulin (mutCALR)-expressing myeloproliferative neoplasms (MPNs). These data – featured today in the Late-Breaking Oral Session (#LB4002) at the European Hematology Association 2025 (EHA2025) Congress in Milan, Italy – focus on the dose escalation portion of thestudies in patients with high risk essential thrombocythemia (ET) who are resistant/intolerant to prior cytoreductive therapy. The studies evaluated the safety and efficacy of INCA033989 in patients with ET as measured by hematologic response and reduction in mutCALR variant allele frequency (VAF). Results as of April 4, 2025, showed rapid and durable normalization of platelet counts across all dose levels, with a trend toward improved responses in higher doses (>400 mg), in patients with
Perma-Pipe International Holdings, Inc. Announces First Quarter Fiscal 2025 Financial Results13.6.2025 16:14:00 EEST | Press release
Perma-Pipe International Holdings, Inc. (NASDAQ: PPIH) announced today financial results for the first quarter ended April 30, 2025. “Sales for the first quarter were $46.7 million, resulting in an increase of $12.4 million, or 36.2%, compared to $34.3 million in the same quarter last year. Net income attributable to common stock of $5.0 million was an increase of $3.6 million, or 243%, compared to $1.4 million in the first quarter of the prior year,” noted President and CEO Saleh Sagr. Backlog currently stands at $131.1 million, a decrease of $7.0 million, compared to $138.1 million at January 31, 2025. However, the Company has experienced a significant increase in backlog of $68.0 million, or 108%, compared to $63.1 million at April 30, 2024. We feel encouraged with the level of backlog we have obtained, which remains more than double the level of reported backlog at the end of the first quarter last year,” Mr. Sagr continued. “Our first quarter results represent unprecedented perfor
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom